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Purpose: In FDG PET/CT, standardized uptake value (SUV) is used to measure metabolic activity but detects
un-phosphorylated FDG as well as phosphorylated FDG (FDG6P). Our aim was to determine the proportions of
intrahepatic and intrasplenic FDG that are phosphorylated after FDG injection and compare them with SUVs.
Methods: Sixty patients undergoing whole-body PET/CT 60 min post-injection of FDG first had dynamic PET imaging
for 30 min with measurement of hepatic and splenic FDG clearances using Patlak-Rutland analysis. The gradient of the
Patlak-Rutland plot, which is proportional to clearance (Ki), was normalized to the intercept, which is proportional to
FDG distribution volume (V(0)) with the same proportionality constant. Using measured values of Ki/V(0), FDG6P/FDG
ratios as functions of time in the two organs were measured for assumed FDG blood disappearance half-times of 40,
50 and 60 min. Hepatic and splenic SUVs were measured from whole-body PET/CT.
Results: The mean (SD) Ki/V(0) was 0.0036 (0.0021) and 0.0060 (0.0041) ml/min/ml for the liver and spleen, respectively,
but the hepatic SUV was 1.36-fold higher than the splenic SUV. This discrepancy was explained by the hepatic
V(0) being 1.6-fold higher than the splenic V(0). The percentages of FDG phosphorylated 60 min post-injection
were 27, 25 and 23% for the liver and 39, 36 and 34% for the spleen, for blood clearance half-times of 40, 50
and 60 min, respectively. SUV indices correlated poorly with Ki/V(0) for both organs.
Conclusions: SUV is largely determined by un-phosphorylated FDG in dynamic exchange with blood FDG, explaining
the poor correlations between SUV indices and Ki/V(0).
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Positron emission tomography (PET) with 2-deoxy-2-
[18F]fluoro-D-glucose (FDG) is widely used to measure
tissue glucose utilization rate (MRglu). MRglu is the
generation rate of glucose-6-phosphate via glucokinase-
mediated phosphorylation. FDG, which is an analogue of
glucose, also undergoes glucokinase-mediated phosphoryl-
ation to FDG-6-phosphate (FDG6P) (Fig. 1). Taking into
account a ‘lumped constant’, introduced to account for* Correspondence: a.m.peters@bsms.ac.uk
1Clinical Imaging Sciences Centre, Brighton Sussex Medical School, Brighton, UK
3Department of Nuclear Medicine, Royal Sussex County Hospital, Eastern
Road, Brighton BN2 5BE, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifdiffering tissue uptake kinetics between glucose and FDG
(for example differing extraction efficiencies), MRglu
(μmol/min/ml) is measured as the tissue FDG clearance
rate (ml/min/ml) multiplied by blood glucose (μmol/ml).
Tissue FDG uptake, however, is often quantified as the
standardized uptake value (SUV) recorded on whole-body
imaging, conventionally 60 min post-injection of FDG.
SUV is defined as follows:
SUV ¼ F=ml  whole body metric ð1Þ
where F/ml is the fraction of administered activity per
ml of tissue; the whole-body metric may be weight
(SUW), lean body mass (LBM; SUL) or body surface
area. Moreover, SUV may be based on the voxel withis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 Model of intrahepatic FDG kinetics. K1 is hepatic blood flow, k2 is a
diffusion constant, k3 the glucokinase and k4 glucose-6-phosphatase. FDG
is assumed to mix throughout its intrahepatic distribution volume
via K1 and k2 by 2–3 min post-injection. De-phosphorylation (via k4) is
assumed to be slow enough to ignore in Patlak-Rutland analysis, which
therefore measures phosphorylation rate. The corresponding model for
the spleen is similar except k4 is lacking
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all voxels in the region of interest (ROI; SUVmean).
In addition to the amount of FDG6P in a tissue, SUV
also depends on the amount of un-phosphorylated FDG,
which is free to exchange between tissue and blood [1–4].
Like FDG clearance, SUV is inversely related to blood
glucose in insulin-insensitive tissues such as tumours [5]
and brain [6, 7]. SUV is therefore a surrogate of FDG
clearance rather than of MRglu and becomes a closer
surrogate of MRglu after normalization to (i.e. multi-
plication by) blood glucose, as recommended in the
European Association of Nuclear Medicine guidelines
on PET/CT [8].
There have been several recent studies of FDG accu-
mulation in the liver, mostly in relation to hepatic stea-
tosis, that have used SUV as the quantitative index of
FDG accumulation and measure of hepatic metabolic ac-
tivity [9–13]. However, these studies have largely ignored
the issue of how much intrahepatic FDG is actually
phosphorylated. The same applies to the spleen, the
metabolic activity of which, almost exclusively based on
SUV in previous PET studies, has attracted a great deal
of recent attention in relation to atherosclerosis [14] and
acute myocardial infarction [15, 16], the so-called
cardio-splenic axis. Using a combined theoretical and
experimental approach, the aim of this study was to de-
termine the proportions of FDG in the liver and spleen
that are phosphorylated at specific post-injection times
and the extent to which SUV reflects FDG clearance in
these two organs.Methods
Theory
The concentration of FDG6P in tissue at time t post-
injection can be calculated from the tissue FDG clearance
(Ki) and the area under the blood time-concentration
curve up to time t (A(t)) as follows.FDG6P ¼ A tð Þ  Ki
MBq=ml ¼ MBq=ml  min½   ml=min=mlð
ð2Þ
The concentration of un-phosphorylated FDG (FDG)
in tissue at time t post-injection can be calculated from
the blood FDG concentration at time t (C(t)),
FDG ¼ C tð Þ  V 0ð Þ
MBq=ml ¼ MBq=ml  ml=mlð Þ ð3Þ
where V(0) is the volume of distribution of FDG in the
tissue (i.e. the virtual volume within which FDG would
be distributed to give an FDG concentration identical to
plasma concentration). (If hepatic FDG concentration
was identical to plasma concentration, then V(0) would
be 1 ml/ml.)
Dividing Eq. 2 by Eq. 3
FDG6P=FDG ¼ A tð Þ=C tð Þ½   Ki=V 0ð Þ½  ð4Þ
Note that A(t)/C(t) is normalised time in a Patlak-
Rutland plot.
There is a very extensive literature on FDG arterial
blood clearance data [1, 2, 17–28], but most publications
aimed to validate simplifications of arterial input and
very few to quantify the kinetics of blood FDG clearance.
From an inspection of published data, the clearance
curve can be seen to be a triple exponential with a very
fast first exponential that is completed within seconds
and a second exponential that is fast with a half-time
of <5 min. The area enclosed by these early exponen-
tials is small compared to the area under the slowest
exponential and can be ignored. Three groups in par-
ticular have published clearance data in large patient
numbers, and from their illustrations, the half-times of
the slow exponentials can be seen to be about 40 min
[23], 50 min [19] or 60 min [21, 22, 25].
Ignoring the fast exponentials, the area under the
blood clearance curve is given as
A tð Þ ¼ N=βð Þ : 1− e−β:t  ð5Þ
where N is the zero time intercept and β the rate con-
stant of the slow exponential,
and
C tð Þ ¼ N :e−β:t ð6Þ
Therefore,
A tð Þ=C tð Þ ¼ 1− e−β:t =β:e−β:t ð7Þ
For blood disappearance half-times of 40, 50 and
60 min, A(t)/C(t) is 105, 94 and 87 min, respectively.
The total tissue concentration of FDG (FDG6P + FDG),
which determines SUV, is given by Eqs. 2 and 3:
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FDG6P þ FDG ¼ V 0ð Þ:A tð Þ: Ki=V 0ð Þ½ ð Þ
þ C tð Þ:V 0ð Þ½  ð9Þ
It can be seen from Eq. 9 that the relationship between
the total activity and Ki/V(0) has a gradient of V(0).A(t)
and an intercept of V(0).C(t).
Combining Eqs. 5, 6 and 9
FDG6P þ FDG ¼ V 0ð Þ: N=βð Þ: 1− e−β:t  : Ki=V 0ð Þ
þ V 0ð Þ:N :e−β:t 
ð10Þ
When t = infinity, it can be seen from Eq. 10 that
FDG6P þ FDG ¼ V 0ð Þ: N=βð Þ: Ki=V 0ð Þð Þ ð11Þ
Therefore, when
Ki=V 0ð Þ ¼ β ð12Þ
FDG6P þ FDG ¼ V 0ð Þ:N ð13Þ
That is, the total activity remains constant as a func-
tion of time following injection when Ki/V(0) = β.
Patients
Sixty patients had dynamic PET prior to routine clinic-
ally indicated PET/CT. These patients formed the study
group for a previous study that investigated the relation-
ships of hepatic MRglu with hepatic steatosis and obesity
[29]. Thirty-eight (including 12 with metabolically active
lymphoma) had FDG-avid malignancy on routine PET/
CT. Forty-seven were men (age range 28–84) and 13 were
women (age 40–67). Nineteen patients had hepatic steato-
sis (CT density ≤40 HU on whole-body PET/CT), 18 were
obese (BMI ≥30 kg/m2) and 5 had type 2 diabetes mellitus
(none with type 1). Five patients had blood glucose
>7 mmol/l, including one with >10 mmol/ml (three of
these five were diabetic). Twelve patients had received
chemotherapy within 6 months of their scan, 19 had re-
ceived chemotherapy >6 months previously and 29 were
chemotherapy-naïve. Patients with known or suspected
high ethanol intake were excluded. All patients gave writ-
ten informed consent for the study, which was approved
by a local institutional review board (NRES Committee
South Central - Oxford C: ref 13/SC/0231).
Whole-body imaging and image analysis
Patients fasted for 6 h before FDG injection. Blood glu-
cose was measured using a glucometer (ACCU-CHEK
Performa; Inform ll strips; USA). Whole-body PET/CT
was performed at 60 min post-injection of ~400 MBq
FDG (not adjusted for body weight) using a Siemens
Biograph 64-slice PET/CT scanner (Erlangen, Germany)with immediate non-enhanced CT scanning (120 Kvp/
50 mA—Care dose 4D; slice 5 mm; pitch 0.8; rotational
speed 0.5/s) for attenuation purposes only. 3D emission
data was then acquired at 3 min per bed position (PET
reconstruction: 4 iterations; subset 8; Gaussian pre-filter;
FWHM 5 mm; matrix size 168 × 168; zoom 1).
Hepatic SUV indices and CT density were measured
from a circular ROI of 3-cm diameter over the right lobe
of the liver, and spleen SUV indices from a circular ROI
of 2.5-cm diameter over the centre of the organ. Body
weight and LBM, estimated from height and weight using
the equations of Boer [30], were used as the whole-body
metrics to give SUW and SUL, respectively. Both were
expressed as the maximum voxel SUV (SUWmax and
SULmax) and mean SUV in the ROI (SUWmean and
SULmean). We assume that because it is soluble in water
rather than fat, negligible FDG enters the fat droplets
in hepatocytes. Using an equation relating fat content
to CT density [31], hepatic SUV was therefore adjusted
for the physical ‘dilutional’ effect of hepatic fat on the
FDG signal, as previously described [32].
Dynamic imaging and image analysis
Prior to whole-body imaging, dynamic imaging was per-
formed as 30 × 1-min frames following FDG injection
with detectors positioned over the torso. Hepatic and
splenic FDG clearances were measured using Patlak-
Rutland graphical analysis from ROI over the liver
(3 cm) and spleen (2.5 cm), each summed from 20 con-
tiguous cranio-caudal transaxial slices, avoiding any sus-
pected focal pathology in each slice, as previously
described [29]. All frames were corrected for physical
decay of 18F. Input function was derived from ROI over
the abdominal aorta, within and avoiding the walls,
summed from about 20 contiguous cranio-caudal transax-
ial slices drawn by a single operator (GK). The gradient of
the plot, which represents tissue FDG clearance (Ki), was
divided by the intercept, which represents tissue distribu-
tion volume of FDG (V(0)—see Eq. 3). There was no need
for attenuation correction of the dynamic study because
the factors that respectively relate gradient and intercept
based on raw count rates to Ki and V(0) are identical, and
cancel out in their ratio, as previously proven [29].
We did not measure the transport constants governing
tissue FDG kinetics shown in Fig. 1. Previous workers
have shown that K1 (which represents tissue blood flow)
and k2 (the constant of diffusion of un-phosphorylated
FDG from tissue to blood) are sufficiently high with re-
spect to the liver that FDG mixes throughout its hepatic
distribution volume within 2–3 min. The first two
frames of the dynamic study (0–1 min and 1–2 min)
over the liver were therefore excluded from the Patlak-
Rutland plot to allow mixing of the FDG throughout its
hepatic distribution volume. The validity of this is
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plot to be essentially linear from the third frame.
Although the corresponding transport constants for the
spleen have not, to our knowledge, been determined, the
plots for the spleen were also linear from the third
frame, suggesting that the mixing time of FDG in splenic
V(0) is as rapid as in liver V(0). Linearity of the plots
also suggests that de-phosphorylation of FDG6P is very
slow. Otherwise, the plot would be convex upwards. De-
phosporylation takes place via glucose-6-phosphatase
(k4), which is absent from the spleen. The essential re-
quirement of the Patlak-Rutland plot for a single trans-
port constant is therefore met for both tissues when the
plot is started from 3 min.
The ratio of FDG6P to total tissue FDG concentration
(FDG6P/[FDG6P + FDG]) was calculated from Eqs. 4
and 7 using A(t)/C(t) based on slow exponential half-
times of 40, 50 and 60 min (corresponding to β of
0.0173, 0.0139 and 0.0115 min−1, respectively). Total 18F
tracer concentrations were estimated using Eq. 9. C(t)
and V(0) are unknown in Eq. 9, so the absolute concen-
tration of tracer is unknown. However, the time courses
of tissue FDG6P + FDG concentration for different
values of Ki/V(0) can be derived because V(0) is inde-
pendent of post-injection time.
Statistics
Using the Shapiro-Wilk test, the W statistic gave p > 0.05
for all SUV indices and Ki/V(0), so parametric statisticsFig. 2 Examples of raw data and Patlak-Rutland plots for the liver and sp
(middle) and spleen (right). Lower panels: Patlak-Rutland plots for the liver
points have been excludedwere used. Values were expressed as mean ± standard
deviation (SD). Pearson’s correlation analysis was used
to assess relationships between SUV indices and Ki/V(0).Results
Ki/V(0)
Representative examples of hepatic and splenic Patlak-
Rutland plots from the same patient are shown in Fig. 2.
Both Patlak-Rutland plots are essentially linear from the
third frame. For all 60 patients, the mean (SD) Ki/V(0)
of the liver was 0.0036 (0.0021) and of the spleen was
0.0060 (0.0041) ml/min/ml (p < 0.0001).Estimations of phosphorylated (FDG6P) and
un-phosphorylated FDG
Using the above mean values of Ki/V(0), the percentages
of FDG phosphorylated 60 min post-injection for blood
clearance half-times of 40, 50 and 60 min were calcu-
lated to be 28, 25, and 23% for the liver and 39, 36 and
34% for the spleen (Fig. 3). In either organ, percentages
approaching 100% would not be achieved until about
4 h post-injection.
Based on a slow exponential half-time of 40 min, it
can be seen from Fig. 4 that total tissue concentration
(FDG6P + FDG) increases or decreases as a function of
post-injection time for values of Ki/V(0) respectively
greater than or less than β (0.0173 ml/min/ml). For slow
exponential half-times of 50 and 60 min, β is 0.0139leen in the same patient. Upper panels: abdominal aorta (left); liver
(left) and spleen (right). Note that for both organs, the first two frame
Fig. 3 Percentage of tissue FDG that is phosphorylated as a function of time after FDG injection shown for slow exponential half-times of 40, 50
and 60 min; left panel: Ki/V(0) = 0.0036 ml/min/ml (typical for the liver); right panel: Ki/V(0) = 0.006 ml/min/ml (typical for the spleen)
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0.0139 and 0.0115 ml/min/ml, respectively.
SUV indices at 60 min post-injection
Hepatic SUV was higher than splenic SUV. Thus, the
liver-to-spleen SUVmean and SUVmax ratios (which, as
ratios, are independent of whole-body metric) were 1.23
(0.24) and 1.36 (0.26), respectively (p < 0.0001 versus 1
for both). SUV indices generally correlated weakly with
Ki/V(0) with respect to both the liver and spleenFig. 4 Time courses of total tissue activity estimated using Eq. 9 for slow e
has been set to unity. The vertical axis is the total tissue activity (FDG6P + FDG
Therefore, when Ki/V(0) = β, the total activity is constant over post-injection tim
fore, for values of Ki/V(0) > 0.0173 ml/min/ml, total activity increases as a funct
ml. The boundary Ki/V(0) value for a slow exponential half-time of 60 min is 0
does not alter these time courses(Table 1). With respect to the liver, but not the spleen,
SUL indices correlated more strongly with Ki/V(0) than
SUW indices, and SUVmax indices correlated more
strongly than SUVmean indices. Adjusting the liver SUVmean
indices for hepatic fat improved their correlations with Ki/
V(0). Relationships of SUV indices with Ki/V(0) had
relatively large intercepts (Fig. 5), which, because SUV
reflects the total tissue concentration, is consistent with
Eq. 9. With respect to the spleen, division of SUV indi-
ces by hepatic SUVmean improved their correlationsxponential half-times of 40 min (left panel) and 60 min (right panel). V0
) normalized to 100. When t is infinity, Ct = 0 and At = N/β (Eqs. 5 and 6).
e. For a slow exponential half-time of 40 min, β = 0.0173 min−1. There-
ion of post-injection time, and vice versa when Ki/V(0) < 0.0173 ml/min/
.0115 ml/min/ml. Ignoring the small areas under the fast exponentials
Table 1 Correlation coefficients (p) of relationships of hepatic
and splenic SUV indices with hepatic and splenic Ki/V(0)
Liver Spleen
SUWmean 0.17 (0.36) 0.24 (0.065)
SUWmax 0.29 (0.045) 0.24 (0.065)
SULmean 0.20 (0.17) 0.25 (0.054)
SULmax 0.38 (0.005) 0.26 (0.045)
FA SUWmean 0.31 (0.030) –
FA SULmean 0.40 (0.0015) –
SUVmean/hepatic SUVmean – 0.40 (0.0015)
SUVmax/hepatic SUVmean – 0.40 (0.0015)
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SUVmax and SUVmean indices.
Discussion
We found that at 60 min post-injection, only about 25%
of FDG is phosphorylated in tissues, such as the liver,
with Ki/V(0) of 0.0036 ml/min/ml, and about 35% in tis-
sues, such as the spleen, with Ki/V(0) of 0.006 ml/min/ml.
The half-time of the assumed exponential decrease in
blood FDG concentration (40, 50 or 60 min) had little
influence on these percentages, although, as would be
expected, the percentages were slightly higher for faster
half-times. The remaining FDG is un-phosphorylated, ex-
changing with blood FDG. These percentages increased at
later times post-injection but did not approach 100% until
several hours post-injection.
Whilst there has been much interest in measuring
FDG clearance in several tissues for many years, thereFig. 5 Relationship between fat-adjusted hepatic SULmean and Ki/V(0)
(see Table 1). Note the large positive zero time intercept, consistent
with Eq. 9has been less interest in the physiological significance of
tissue FDG distribution volume. Yet, as shown here,V(0)
is critical in determining the proportion of FDG in a
tissue that is actually phosphorylated. Several studies
have reported how the SUVs of various tissues change
between imaging at 60 min and delayed imaging, with
some tissues showing an increase and others, notably the
liver and spleen, showing a decrease in SUV [33–37]. The
magnitudes and directions of the changes are determined
by Ki/V(0). Thus, when Ki/V(0) is higher than β, there is
an increase in SUV and vice versa when Ki/V(0) is lower
than β. The issue of early versus delayed imaging is likely
to increase in importance with the development of new
whole-body PET machines such as UltraPET [38].
In the measurement, by computer modelling, of the
transport constants in Fig. 1, previous workers have
stressed the importance of considering the liver’s dual
blood supply [1–3, 39]. There is general agreement,
however, that Patlak-Rutland analysis, although less in-
formative, is not influenced by the dual blood supply
and is more robust than computer modelling for the
measurement of Ki and V(0). Table 2 summarizes values
of Ki and V(0) obtained by previous workers using com-
puter modelling and Patlak-Rutland analysis. It can be
seen from this Table that in humans, there is good
agreement between modelling and Patlak-Rutland ana-
lysis [2] and that our mean value of Ki/V(0) for the liver,
based on Patlak-Rutland analysis, is similar to previously
published values in humans based on both modelling
and Patlak-Rutland analysis [1, 2]. In anaesthetised pigs,
Ki based on modelling was somewhat higher than hu-
man values [3]. Patlak-Rutland analysis, however, gave
values of Ki/V(0) in line with other studies and our own
values [1–3]. We can conclude therefore that our esti-
mate of Ki/V(0) for the liver is reliable. We could find
no corresponding literature values for the spleen.Table 2 Hepatic Ki and V(0) determined by previous workers
[1–3] using computer modelling and Patlak-Rutland graphical
analysis
Modelling Graphical analysis
Ki V(0) Ki/V(0) Ki V(0) Ki/V(0)
Choi et al. [1] 0.0043 0.88a 0.0049 ND ND ND
Iozzo et al. [2] 0.0029 0.81 0.0036 0.0023 0.84b 0.0029b
Munk et al. [3]c 0.0078 0.95 0.0082 0.0037 1.05 0.0035
Ki and V(0) based on modelling have been calculated using the equations
linking Ki and V(0) to the transport constants (e.g. Ki = K1 × k3/[k2 + k3] and
V(0) = K1/[k2 + k3])





bValues from single illustrated Patlak-Rutland plot (mean of group values not given)
cAnaesthetized pigs
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SUV even though it had a higher Ki/V(0). As shown in
the Appendix, this is the result of a lower distribution
volume in the spleen. Considering the relative values of
hepatic and splenic SUVmax and Ki/V(0), hepatic V(0)
can be calculated to be 1.6-fold higher than splenic V(0)
(see Appendix).
SUV depends on the total tissue FDG concentration
(FDG plus FDG6P), which partly explains the weak cor-
relations we found between SUV indices and Ki/V(0) for
both the liver and spleen. Interestingly, the strongest
correlations were found with SUL indices, which support
the use of LBM for calculating SUV [40]. The poor
correlations of hepatic SUVmean indices with Ki/V(0) is
explained by the physical effect of hepatic fat on the
FDG signal—a ‘fat-diluting’ effect that has previously
been described to affect SUVmax less than SUVmean [32].
Making the described adjustment for hepatic fat gave
SUVmean a stronger correlation with Ki/V(0) compared
with the corresponding unadjusted values (approximately
doubling the correlation coefficients for both SUWmean
and SULmean; Table 1). With respect to the spleen, correla-
tions were similar for SUVmax and SUVmean indices be-
cause fat is not an issue in the spleen. Interestingly, the
strongest correlation with Ki/V(0) was seen when splenic
SUV was divided by hepatic SUV. Others have previously
shown that division of tissue SUV by blood pool SUV
makes it a better surrogate of clearance than SUV alone
[41, 42]. As shown here, hepatic SUV is largely a blood
pool SUV, explaining this finding.
A potential limitation of Patlak-Rutland analysis is the
influence of glucose-6-phosphatase (k4), which if active
would invalidate the requirement for a single transport
pathway. Previous workers in this field, however, also
recorded linear hepatic Patlak-Rutkand gradients, sug-
gesting that de-phosphorylation is very slow [1–3]. In
any event, we avoided a longer acquisition period in order
to minimize a possible influence of de-phosphorylation on
the gradient.
Study limitations include firstly the recruitment of
patients with co-existing morbidity. Secondly, hepatic fat
distribution is heterogeneous [43], so measurement of
CT density in a single ROI for the hepatic fat adjustment
procedure may be misleading. Moreover, CT is not
regarded as the gold standard imaging technique for
quantifying steatosis, but probably instead MRI and MR
spectroscopy [44]. The duration of our dynamic acquisi-
tion may be considered limited but longer acquisition
periods risk patient movement artefacts, especially in
patient participants rather than motivated normal volun-
teers [1, 2, 4], as well as a possible influence of de-
phosphorylation, so 30 min seemed reasonable. Others
used 40 [2, 4] or 60 min [1]. A 2-min mixing time of
FDG throughout the hepatic distribution volume mayseem brief but is consistent with previously reported
values of K1 and k2, which respectively ranged from 0.01
to 0.015 and 0.013 to 0.016 s−1 [1–3], and which therefore
give an equilibration rate constant of 0.023–0.031 s−1. This
gives a time to 95% equilibration of FDG between compart-
ments 1 and 2 of 97–130 s. Munk et al. also found from
rapid early sampling that equilibration was achieved within
a few minutes [3]. We used abdominal aorta for arterial in-
put but others have validated the abdominal aorta for
Patlak-Rutland analysis [28, 45], including for the liver [45].
Conclusions
In conclusion, tissue FDG6P concentration depends on
FDG clearance per unit total volume but the FDG6P/
FDG concentration ratio depends on tissue clearance
per unit distribution volume. Because the majority of
FDG is un-phosphorylated, SUV in both the liver and
spleen largely reflects blood pool activity, especially the
liver, explaining the poor correlations between SUV indi-
ces and Ki/V(0). If SUV is to be used as a measure of
FDG clearance and metabolic activity, then LBM is the
preferred whole-body metric with which to calculate it.
Appendix
Equation 9 can be re-written, replacing FDG6 + FDG
with SUV, for both liver (L) and spleen (S).
SUVS
SUVL
¼ ðV ð0Þ:AðtÞ:½Ki=V ð0ÞSÞ þ V ð0ÞS:CðtÞ
ðV ð0Þ:AðtÞ:½Ki=V ð0ÞLÞ þ V ð0ÞL:CðtÞ
ðA1Þ
Note that administered activity and whole-body metric
cancel out when the two SUVs are expressed as a ratio,
which then becomes the ratio of the total FDG concen-
trations in the two organs.
Therefore, re-arranging and dividing numerator and
denominator in Eq. A1 by C(t)
Vð0ÞL
Vð0ÞS
¼ SUVL  ½AðtÞ=CðtÞ:½Ki=V ð0ÞS þ 1Þ
SUVS  ½AðtÞ=CðtÞ:½Ki=V ð0ÞL þ 1Þ
ðA2Þ
For disappearance exponential half-times of 40, 50 and
60 min, A(t)/C(t) is 105, 94 and 87 min, respectively. So
for SUVL/SUVS of 1.36 (see the “Results” section), the
corresponding values of V(0)L/V(0)S would be 1.61, 1.59
and 1.58.
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